Suzhou GenAssist Therapeutic Co.,Ltd recently announced that its first base editing product, GEN6050, has submitted a pre-IND application to the FDA and has been accepted

SUZHOU, China, May 6, 2023 /PRNewswire/ — Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA. GEN6050 is an in vivo base editing drug that targets exon 50 skipping in the Duchenne…